RxDoctor Payments Data

Charles Craton, MD

Internal Medicine · Douglasville, GANPI 1568435501

Payments from drug & device makers

$13,364in general payments, 2019–2025

Across 799 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Amgen$1K
  • Lilly USA, LLC$995
  • Amarin Pharma, Inc.$688
  • AbbVie$687
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$13,299100%
  • Education$640%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,364 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$103,710
Medicare patients
285
Services billed
1,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$104,614
JardianceEmpagliflozin64$61,407
FarxigaDapagliflozin Propanediol20$22,969
EliquisApixaban29$19,777
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,771
Soliqua 100-33Insulin Glargine/Lixisenatide19$17,713
JanuviaSitagliptin Phosphate19$17,360
Tresiba Flextouch U-100Insulin Degludec31$15,284
Xigduo XrDapaglifloz Propaned/Metformin18$13,556
Synjardy XrEmpagliflozin/Metformin Hcl12$13,219
JanumetSitagliptin Phos/Metformin Hcl13$10,272
Repatha SureclickEvolocumab15$7,950
Prednisolone19$5,006
Fentanyl11$4,813
VascepaIcosapent Ethyl14$4,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,085$104,61480 claims
Boehringer IngelheimJardiance, Synjardy Xr$611$74,62676 claims
MerckJanuvia, Janumet$250$27,63232 claims
AstraZenecaFarxiga, Symbicort$1,912$25,69432 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$385$24,50656 claims
PfizerEliquis$460$19,77729 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$405$17,71319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Douglasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →